98%
921
2 minutes
20
Introduction And Objectives: We aimed to describe the clinical outcomes of the use of the CentriMag acute circulatory support system as a bridge to emergency heart transplantation (HTx).
Methods: We conducted a descriptive analysis of the clinical outcomes of consecutive HTx candidates included in a multicenter retrospective registry who were treated with the CentriMag device, configured either for left ventricular support (LVS) or biventricular support (BVS). All patients were listed for high-priority HTx. The study assessed the period 2010 to 2020 and involved 16 transplant centers around Spain. We excluded patients treated with isolated right ventricular support or venoarterial extracorporeal membrane oxygenation without LVS. The primary endpoint was 1-year post-HTx survival.
Results: The study population comprised 213 emergency HTx candidates bridged on CentriMag LVS and 145 on CentriMag BVS. Overall, 303 (84.6%) patients received a transplant and 53 (14.8%) died without having an organ donor during the index hospitalization. Median time on the device was 15 days, with 66 (18.6%) patients being supported for> 30 days. One-year posttransplant survival was 77.6%. Univariable and multivariable analyses showed no statistically significant differences in pre- or post-HTx survival in patients managed with BVS vs LVS. Patients managed with BVS had higher rates of bleeding, need for transfusion, hemolysis and renal failure than patients managed with LVS, while the latter group showed a higher incidence of ischemic stroke.
Conclusions: In a setting of candidate prioritization with short waiting list times, bridging to HTx with the CentriMag system was feasible and resulted in acceptable on-support and posttransplant outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rec.2023.05.002 | DOI Listing |
J Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
JPEN J Parenter Enteral Nutr
September 2025
Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia.
Background: Hospitalized patients may require nutrition support because of inadequate intake or impaired gut function. Enteral nutrition is preferred over parenteral nutrition because of fewer complications and earlier return of gut function. This study describes peripheral parenteral nutrition (PPN) use in an Australian tertiary center, evaluating its indications, incidence of adverse effects, and outcomes without the support of a nutrition support service.
View Article and Find Full Text PDFBackground: Pressure injuries are common, difficult to manage, and carry a high economic burden. They are challenging to physicians and a burden to society.
Case Report: An 89-year-old male, who had previously undergone internal fixation with screws and rods for a right intertrochanteric fracture, developed a deep circular open ulcer measuring 11 cm × 7.
Wounds
August 2025
Solventum, Maplewood, MN, USA.
Background: Initially limited to inpatient use, negative pressure wound therapy (NPWT) is now frequently used in community settings. However, complexities in wound management step-down strategies in the United Kingdom, including regional variations in referral processes, lack of consensus on funding criteria, and limited availability of NPWT units, have led to extended hospital length of stay (LOS) for patients ready for discharge but still needing NPWT. Single-use NPWT (sNPWT) can serve as a bridge between hospital and community NPWT.
View Article and Find Full Text PDFKnee Surg Relat Res
September 2025
Florida Orthopaedic Institute, Gainesville, FL, 32607, USA.
Background: A clear understanding of minimal clinically important difference (MCID) and substantial clinical benefit (SCB) is essential for effectively implementing patient-reported outcome measurements (PROMs) as a performance measure for total knee arthroplasty (TKA). Since not achieving MCID and SCB may reflect suboptimal surgical benefit, the primary aim of this study was to use machine learning to predict patients who may not achieve the threshold-based outcomes (i.e.
View Article and Find Full Text PDF